Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Antengene Completes $120 Million Series B for China Clinical Trials

publication date: Jan 2, 2019

Antengene, an innovative Shanghai biopharma, has completed a $120 million Series B financing led by Boyu Capital and FountainVest. The company intends to use the financing to fund China clinical trials of its in-licensed lead programs, ATG-008 and ATG-010 (selinexor), and other clinical-stage assets. It will also expand its pipeline through internal R&D and external partnerships as it prepares for commercial operations. In 2017, Antegene raised $21 million in an A round led by Qiming Venture. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital